Zevra Therapeutics, Inc. Common Stock
$11.88
$0.08 (+0.68%)
$11.79Day Range$12.29
Key Statistics
Market Cap
$700.73M
Shares Outstanding
59.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 16, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$11.96
Day High
$12.29
Day Low
$11.79
Volume
986.8K
VWAP
$12.08
Prev Close
$11.80
Transactions
--
Acc. Volume
--
About Zevra Therapeutics, Inc. Common Stock
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
PHARMACEUTICAL PREPARATIONSSIC 283461 employees101 FEDERAL STREET, BOSTON, MA, 02110(888) 958-1253IPO Apr 16, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001434647
- Composite FIGI
- BBG0026ZG1F5
- Share Class FIGI
- BBG0026ZG1G4
- Ticker Root
- ZVRA
- SIC Code
- 2834
About Zevra Therapeutics, Inc. Common Stock (ZVRA) Stock
Zevra Therapeutics, Inc. Common Stock (ZVRA) closed the 2026-09-17 session at $11.88, up 0.68% versus the previous close (+0.08). The stock opened at $11.96 and traded between $11.79 and $12.29 during that session. Session trading volume was 987K shares. The volume-weighted average price (VWAP) is $12.08.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Zevra Therapeutics, Inc. Common Stock has a market capitalization of $700.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ZVRA is listed on the XNAS exchange. The company employs approximately 61 people. Zevra Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2015-04-16.
On this page you can find market ZVRA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.